ArticleScience advances2026
Bandgap-enabled ultrasound tissue marking by a biodegradable metastructured hydrogel implant.
Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Implantation of tissue markers within lesions is standard practice in breast cancer diagnosis and treatment, which provides critical guidance for regular follow-up and precise surgical localization. However, the identification of existing markers is limited by nonspecificity and low resolution of conventional ultrasound imaging. The use of rigid materials to compensate for this constraint has resulted in inadequate biodegradability and biocompatibility. Here, we propose a biodegradable metastructured hydrogel tissue marker with acoustic bandgaps enabling specific ultrasonic reflection spectra. Through frequency-to-color mapping on B-mode images, visualization is achieved, with scalable designs allowing multiple marker distinction. Deliverable via an 18-gauge puncture needle and featuring tissue-mimicking softness, the metagel marker mitigates displacement risks, tissue damage, and inflammation. Live pig experiments demonstrate clear identification and dynamic stability. Six-week rat studies confirm long-term marking ability and biocompatibility. These results support the metagel marker's clinical potential for breast cancer management and precise therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.